Recently, JPMorgan Chase & Co (Symbol: JPM) shares have outperformed the average analyst 12-month target price of $217.92, currently trading at $222.29 per share. When a stock exceeds its projected target, analysts typically face two choices: downgrade the stock based on valuation or raise their price targets. Their decision often hinges on the company’s underlying fundamental performance. If conditions are improving for JPMorgan, raising the target could be warranted.
The estimated target prices for JPMorgan Chase come from 22 analysts within the Zacks coverage universe. While the average is an important benchmark, it’s important to recognize the range: for instance, one analyst projects a target of $185.00, while another sets theirs as high as $237.00. The standard deviation among these estimates is $15.192, indicating variability in expectations.
Investors often analyze the average price target as a reflection of collective insights, rather than relying solely on one expert’s opinion. With JPMorgan now above the average target of $217.92, this presents a critical moment for investors. They must consider whether this price is a stepping stone toward even higher targets or if the valuation has become too inflated, prompting a reevaluation of their holdings.
Recent JPM Analyst Ratings Breakdown | ||||
---|---|---|---|---|
» | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
Strong buy ratings: | 13 | 15 | 16 | 16 |
Buy ratings: | 1 | 1 | 1 | 1 |
Hold ratings: | 8 | 7 | 6 | 6 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.77 | 1.65 | 1.57 | 1.57 |
The average rating is based on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 signals a Strong Sell. Data for this article was sourced from Zacks Investment Research via Quandl.com. Investors can access the latest Zacks research report on JPM—FREE.
The Top 25 Broker Analyst Picks of the S&P 500 »
Also see:
• NWLI Insider Buying
• Top Ten Hedge Funds Holding HILT
• CBD Videos
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.